Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Taxes (2016 - 2023)

Harvard Bioscience (HBIO) has disclosed Current Taxes for 14 consecutive years, with $398000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Current Taxes rose 665.38% to $398000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $398000.0, a 665.38% increase, with the full-year FY2021 number at $224000.0, down 21.68% from a year prior.
  • Current Taxes was $398000.0 for Q2 2023 at Harvard Bioscience, down from $700000.0 in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $1.3 million in Q1 2019 to a low of $52000.0 in Q2 2022.
  • A 5-year average of $552642.9 and a median of $576500.0 in 2019 define the central range for Current Taxes.
  • Peak YoY movement for Current Taxes: soared 3121.05% in 2019, then crashed 90.44% in 2022.
  • Harvard Bioscience's Current Taxes stood at $609000.0 in 2019, then crashed by 53.04% to $286000.0 in 2020, then fell by 21.68% to $224000.0 in 2021, then crashed by 76.79% to $52000.0 in 2022, then soared by 665.38% to $398000.0 in 2023.
  • Per Business Quant, the three most recent readings for HBIO's Current Taxes are $398000.0 (Q2 2023), $700000.0 (Q1 2023), and $52000.0 (Q2 2022).